ARTICLE | Clinical News
Adzenys XR-ODT amphetamine regulatory update
February 1, 2016 8:00 AM UTC
FDA approved an NDA from Neos for Adzenys XR-ODT amphetamine to treat ADHD in patients ages >=6. Neos plans to launch the drug next quarter. The extended-release, orally disintegrating tablet formulation of amphetamine polistirex uses Neos’ Rapidly Disintegrating Ionic Masking (RDIM) technology. ...